We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Correspondence |

Efalizumab and Progression of Undiagnosed Follicular Mycosis Fungoides—Reply

Sophie M. Worobec, MD
Arch Dermatol. 2009;145(7):844. doi:10.1001/archdermatol.2009.133.
Text Size: A A A
Published online


In reply

We respectfully disagree with Di Lernia's comment that patients with pilar MF, F-MF, or folliculotropic cutaneous T-cell lymphoma (CTCL) “should always be considered to have tumor-stage disease.”

We are familiar with the 2002 article by van Doorn et al1 that describes 51 patients with F-MF who had disease-specific survival rates of 68% at 5 years and 26% at 10 years and posits that the prognosis for F-MF is similar to that for epidermotropic tumor-stage disease.1 However, Di Lernia did not cite 2 more recent reports that give much better survival rates for F-MF. In a 2005 report,2 the European Organization for Research on the Treatment of Cancer classifies F-MF as a distinct subgroup. The 5-year survival rate of 86 patients with F-MF is reported to be 80%, while that of 800 patients with classic MF is 88%.2 A 2008 report by Gerami et al3 comparing a United States group of 43 patients with F-MF to age- and stage-matched patients with epidermotropic MF found that those with early F-MF (up to and including stage IIA) had a 10-year survival of 82% and a 15-year survival rate of 41%. The 43 control patients who had epidermotropic MF had a 91% survival rate at both 10 and 15 years. However, patients with later-stage F-MF (stage IIB or higher) had outcomes similar to those with conventional epidermotropic MF of a similar stage. And the 10-year progression-free survival rate was 25% in the patients with stage IIB or higher F-MF compared with 8% in the epidermotropic MF group. While the authors conclude that F-MF is a more aggressive variant of CTCL, especially in the early stages, there was no evidence of worse prognosis in stage IIB or more advanced disease.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





July 1, 2009
Vito Di Lernia, MD
Arch Dermatol. 2009;145(7):843-844. doi:10.1001/archdermatol.2009.132.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Immunobiologics in the treatment of psoriasis. Clin Immunol 2007;123(2):129-38.
Efalizumab and progression of undiagnosed follicular mycosis fungoides. Arch Dermatol 2009;145(7):843-4; author reply 844.